June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Increased Public Interest in Pilocarpine Drops for Presbyopia following Regulatory Approval and Direct-to-Consumer Ad Campaigns: A Google Trends Analysis
Author Affiliations & Notes
  • Jonathan D. Tijerina
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Matthew J Parham
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Samuel Cohen
    Ophthalmology, Stanford University School of Medicine, Stanford, California, United States
  • Hasenin Al-Khersan
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Jonathan Tijerina None; Matthew Parham None; Samuel Cohen None; Hasenin Al-Khersan RegenX, Code C (Consultant/Contractor), Genentech, Code S (non-remunerative), Eye Point, Code S (non-remunerative)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3034. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan D. Tijerina, Matthew J Parham, Samuel Cohen, Hasenin Al-Khersan; Increased Public Interest in Pilocarpine Drops for Presbyopia following Regulatory Approval and Direct-to-Consumer Ad Campaigns: A Google Trends Analysis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3034.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize how media coverage and direct-to-consumer advertising affected public interest in 1.25% pilocarpine drops based on Google Trends analysis of internet search traffic.

Methods : Retrospective descriptive cross-sectional study. Relative search volume databases were generated by Google Trends for keywords related to 1.25% pilocarpine using searches in the United States from January 1, 2004 to June 14, 2022. All data extraction and analyses were conducted on June 14, 2022. All queries entered into Google search engine within the United States during study period were extracted. Changes in monthly relative search volumes were calculated for keywords “presbyopia”, “vuity”, “pilocarpine”, and “pilocarpine presbyopia”, following October 2021 FDA approval and March 2022 commercial advertisement.

Results : From January 2004 through October 2021 , relative search volumes (RSV) demonstrated a mean (SD) RSV of 0.005% (0.07) for “vuity”, 61.30% (10.33) for “presbyopia”, 41.97% (7.91) for “pilocarpine”, and 1.44% (7.67) for “pilocarpine presbyopia”. Mean RSV from November 2021 through February 2022 increased to 21.75% for “vuity”, a percent change of +465339.8%, 89.75% for “presbyopia”, a percent change of +46.4%, 55.75% for “pilocarpine”, a percent change of +32.8%, and 37.50%, for “pilocarpine presbyopia”, a percent change of +2505.5%. All terms further increased from March 2022 through June 2022. Average RSV increased to 74.00%
for “vuity”, an additional percent change of +240.2%, 91.67% for “presbyopia”, a percent change of +2.1%. 86.67% for “pilocarpine”, a percent change of +55.5%, and 61.00% for “pilocarpine presbyopia”, a percent change of +62.7%.

Conclusions : Both press coverage following regulatory body approval and direct-to-consumer advertising campaigns for 1.25% pilocarpine HCl were associated with an increase in internet search traffic for related keywords. Google Trends may represent a convenient tool with powerful analytical insights into rapidly emerging patterns in public interest.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Mean RSV in the US for pilocarpine-related keywords pre-/ post-FDA Approval and DTC Ads. Vuity (blue), presbyopia (red), pilocarpine (green), pilocarpine presbyopia (orange)

Mean RSV in the US for pilocarpine-related keywords pre-/ post-FDA Approval and DTC Ads. Vuity (blue), presbyopia (red), pilocarpine (green), pilocarpine presbyopia (orange)

 

Mean RSV in the US for 1.25% pilocarpine-related keywords January 2018 – June 2022. Vuity (blue), presbyopia (red), pilocarpine (green), and pilocarpine presbyopia (orange)

Mean RSV in the US for 1.25% pilocarpine-related keywords January 2018 – June 2022. Vuity (blue), presbyopia (red), pilocarpine (green), and pilocarpine presbyopia (orange)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×